European Medicines Agency

Last updated

European Medicines Agency
European Medicines Agency.svg
Vivaldigebouw 2019.10.24 (1).jpg
EMA headquarters in Amsterdam
Agency overview
Formed1 January 1995;29 years ago (1995-01-01)
Jurisdiction European Union
Headquarters Amsterdam, Netherlands [1]
MottoScience. Medicines. Health.
Employees897 [2]
Annual budget€478.4 million (2024) [3]
Agency executives
  • Emer Cooke, Executive Director
  • Christa Wirthumer-Hoche, Chairperson
Key document
Website ema.europa.eu
Map
Europe EU laea location map.svg
Red pog.svg
Amsterdam
European Medicines Agency (European Union)

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA). [4] [5]

Contents

The EMA was set up in 1995, with funding from the European Union and the pharmaceutical industry, as well as indirect subsidy from member states, its stated intention to harmonise (but not replace) the work of existing national medicine regulatory bodies. The hope was that this plan would not only reduce the €350 million annual cost drug companies incurred by having to win separate approvals from each member state but also that it would eliminate the protectionist tendencies of sovereign states unwilling to approve new drugs that might compete with those already produced by domestic drug companies.

The EMA was founded after more than seven years of negotiations among EU governments and replaced the Committee for Proprietary Medicinal Products and the Committee for Veterinary Medicinal Products, though both of these were reborn as the core scientific advisory committees. The agency was located in London prior to the United Kingdom's vote for withdrawal from the European Union, relocating to Amsterdam in March 2019. [6] [7]

Operations

The European Medicines Agency (EMA) operates as a decentralised scientific agency (as opposed to a regulatory authority) of the European Union (EU) and its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use. [8] More specifically, it coordinates the evaluation and monitoring of centrally authorised products and national referrals, develops technical guidance and provides scientific advice to sponsors. Its scope of operations is medicinal products for human and veterinary use including biologics and advanced therapies, and herbal medicinal products. The agency is composed of the Secretariat (ca. 600 staff), a management board, seven scientific committees (human, veterinary and herbal medicinal products, orphan drugs, paediatrics, advanced therapies and pharmacovigilance risk assessment) and a number of scientific working parties.

The Secretariat is organised into five units: Directorate, Human Medicines Development and Evaluation, Patient Health Protection, Veterinary Medicines and Product Data Management, Information and Communications Technology and Administration. The Management Board provides administrative oversight to the Agency: including approval of budgets and plans, and selection of executive director. The Board includes one representative of each of the 27 Member States, two representatives of the European Commission, two representatives of the European Parliament, two representatives of patients' organisations, one representative of doctors' organisations and one representative of veterinarians' organisations. The Agency decentralises its scientific assessment of medicines by working through a network of about 4500 experts throughout the EU. The EMA draws on resources of over 40 National Competent Authorities (NCAs) of EU Member states.

The EMA additionally engages with international agencies and non-governmental organizations on areas of mutual interest, such as its participation on the Coalition for Epidemic Preparedness Innovations' Joint Coordination Group. [9] It is also a benefactor of Health Level Seven International, [10] a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [11] and the International Pharmaceutical Regulators Programme (IPRP), [12] and a partner of the Society for Immunotherapy of Cancer [13] and Vaccine Confidence Project. [14]

Committees

Medicinal products for human use

A single evaluation is carried out through the Committee for Medicinal Products for Human Use (CHMP). [15] If the Committee concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. This is sent to the European Commission to be transformed into a marketing authorisation valid for the whole of the EU. A special type of approval is the paediatric-use marketing authorisation (PUMA), which can be granted for medical products intended exclusively for paediatric use. [16]

The CHMP is obliged by the regulation to reach decisions within 210 days, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data. [17]

The review process of the European Medicines Agency regarding medical issues has been criticized for its lack of transparency. [18] In a rebuttal of an EMS review that included her work, Louise Brinth, a Danish physician, noted that "experts" reviewing data remain unnamed and seem to be bound to secrecy. Minutes are not released and diverging opinions are not reported suggesting that all the "experts" are of the same opinion. In her view the process is unscientific and undemocratic. [19]

Medicinal products for veterinary use

The Committee for Medicinal Products for Veterinary Use (CVMP) operates in analogy to the CHMP as described above. [20]

Orphan medicinal products

The Committee on Orphan Medicinal Products (COMP) administers the granting of orphan drug status since 2000. Companies intending to develop medicinal products for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than five in 10,000 persons in the European Union can apply for 'orphan medicinal product designation'. The COMP evaluates the application and makes a recommendation for the designation which is then granted by the European Commission. [21]

Herbal medicinal products

The Committee on Herbal Medicinal Products (HMPC) assists the harmonisation of procedures and provisions concerning herbal medicinal products laid down in EU Member States, and further integrating herbal medicinal products in the European regulatory framework since 2004. [22]

Paediatry

The Paediatric Committee (PDCO) deals with the implementation of the paediatric legislation in Europe Regulation (EC) No 1901/2006 since 2007. Under this legislation, all applications for marketing authorisation of new medicinal products, or variations to existing authorisations, have to either include data from paediatric studies previously agreed with the PDCO, or obtain a PDCO waiver or a deferral of these studies. [23]

Advanced therapies

The Committee for Advanced Therapies (CAT) was established in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) such as gene therapy, somatic cell therapy and tissue engineered products. It assesses the quality, safety and efficacy of ATMPs, and follows scientific developments in the field. [24]

Pharmacovigilance risk assessment

A seventh committee, the Pharmacovigilance Risk Assessment Committee (PRAC) has come into function in 2012 with the implementation of the new EU pharmacovigilance legislation (Directive 2010/84/EU). [25]

Other activities

The Agency carries out a number of activities, including:

Centralised marketing authorisations

The centralised procedure allows companies to submit a single application to the agency to obtain from the European Commission a centralised (or "community") marketing authorisation (MA) valid in all European Union member states and in Iceland, Liechtenstein and Norway. [26] The centralised procedure is compulsory for all medicines derived from biotechnology and other high-tech processes, as well as for human medicines for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases, and for veterinary medicines for use for growth or yield enhancers. It is also compulsory for advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and for orphan medicines (for rare diseases). The centralised procedure is also open to products that bring a significant therapeutic, scientific or technical innovation, or is in any other respect in the interest of patient or animal health. As a result, the majority of genuinely novel medicines are authorised through the EMA.

For products eligible for or requiring centralised approval, a company submits an application for a marketing authorisation to the EMA.

History

1995-2004: Inception

The EMA was set up in 1995, with funding from the European Union and the pharmaceutical industry, as well as indirect subsidy from member states, its stated intention to harmonise (but not replace) the work of existing national medicine regulatory bodies. The hope was that this plan would not only reduce the €350 million annual cost drug companies incurred by having to win separate approvals from each member state but also that it would eliminate the protectionist tendencies of Sovereign states unwilling to approve new drugs that might compete with those already produced by domestic drug companies.[ citation needed ]

The EMA was founded after more than seven years of negotiations among EU governments and replaced the Committee for Proprietary Medicinal Products and the Committee for Veterinary Medicinal Products, though both of these were reborn as the core scientific advisory committees. The agency was located in London prior to the United Kingdom's vote for withdrawal from the European Union, relocating to Amsterdam in March 2019. [6] [7]

2004: Renaming

Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA). [4] [5]

The EMA contributed to the Global Vaccine Action Plan developed by the Decade of Vaccines Collaboration, endorsed by the 194 Member States of the World Health Assembly in May 2012, and published on the World Health Organization's website in February 2013. [27]

2019: Relocation

Following the 2016 decision of the United Kingdom to leave the European Union ("Brexit"), the EMA chose to search for another base of operations. According to EU Law the European Commission had to decide on the fate of the EMA's location. The EU ministers met to vote on their preferred successor. [28] The EU's Health Commissioner Vytenis Andriukaitis said that the preferred choice would be a location where an "easy set up and guarantee of smooth operations" would be available. Member states who had expressed their bid for the new EMA location were Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden (or in other words all remaining member countries except for the Baltic States and Luxembourg). [29] [30] [31] [32] [33] [34] [35] [36] [37] [38]

It had also been speculated that the Strasbourg-based seat for the European Parliament could be moved to Brussels, in exchange for the city to host the EMA. [39] Others speculated on the merits of Amsterdam, well before the final decision was made. [40] [41]

The decision on the relocation was made on 20 November 2017, during the EU General Affairs Council meeting, [41] after three voting rounds and finally drawing of lots. After the first round of voting, Milan (25 votes), Amsterdam (20 votes) and Copenhagen (20 votes) were the only contenders left. After the second voting round, two cities were left: Milan (twelve votes) and Amsterdam (nine votes). These two cities tied in the subsequent vote (thirteen votes each), after which a drawing of lots identified Amsterdam as the host city of EMA. [42]

EMA staff left its London premises in March 2019 to relocate to a temporary building in Amsterdam, and by January 2020 the relocation to the permanent building in Amsterdam Zuidas district was finalised. [1]

2020: COVID-19

The EMA played a significant role in the response to the COVID-19 pandemic in the European Union, seeking to expedite the development and approval of COVID-19 vaccines and treatments. [43]

It participated in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership hosted by the Foundation for the National Institutes of Health, collaborating with international government agencies and corporations to coordinate a research strategy for prioritizing and speeding up development of COVID-19 vaccines and pharmaceutical products. [44]

While in the process of evaluating the Pfizer–BioNTech COVID-19 vaccine in December 2020, the EMA suffered a cyberattack, resulting in the leak of classified regulatory documents to journalists, academics and the public via the dark web. [45] [46] [47] The documents revealed internal concerns about low production quality in the mRNA vaccine candidate, and regulators' efforts to have Pfizer and BioNTech rectify these deficiencies. [48] [49] [50] The EMA ultimately authorized the vaccine on 21 December 2020, satisfied that the product quality was "sufficiently consistent and acceptable." [51] [52]

Comparison with other medical regulatory agencies

As of 2016, the EMA was roughly parallel to the drug part of the U.S. Food and Drug Administration (FDA), [53] but without centralisation. [54] The timetable for product approval via the EMA's centralised procedure of 210 days compares well with the average of 500 days taken by the FDA in 2008 to evaluate a product. [55]

See also

Related Research Articles

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

Pharmacovigilance, also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigilare. As such, pharmacovigilance heavily focuses on adverse drug reactions (ADR), which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

<span class="mw-page-title-main">Nimesulide</span> Anti-inflammatory drug

Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) with pain medication and fever reducing properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis, and primary dysmenorrhoea in adolescents and adults above 12 years old.

EudraVigilance is the European data processing network and management system for reporting and evaluation of suspected adverse reactions to medicines which have been authorised or being studied in clinical trials in the European Economic Area (EEA). The European Medicines Agency (EMA) operates the system on behalf of the European Union (EU) medicines regulatory network.

<span class="mw-page-title-main">EudraLex</span> EU laws on medicinal products

EudraLex is the collection of rules and regulations governing medicinal products in the European Union.

EUDRANET, the European Telecommunication Network in Pharmaceuticals, is an IT platform to facilitate the exchange of information between regulatory partners and industry during submission and evaluation of applications. The aim of EUDRANET is to provide appropriate secure services for inter-Administration data interchange and for exchanges between Administrations and industry. EUDRANET is based on the TESTA backbone infrastructure provided by the IDA Programme.

Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23.

<span class="mw-page-title-main">European Directorate for the Quality of Medicines & HealthCare</span> International organisation

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia.

<span class="mw-page-title-main">Pradofloxacin</span> Chemical compound

Pradofloxacin, sold under the brand name Veraflox, is a third-generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, Animal Health GmbH, and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of bacterial infections in dogs and cats.

In the European Union, the Qualified Person Responsible For Pharmacovigilance (QPPV) is an individual, usually an employee of a pharmaceutical company, who is personally responsible for the safety of the human pharmaceutical products marketed by that company in the EU. This function was established in 2004 by article 23 of regulation (EC) No 726/2004. The article establishes that the holder of a marketing authorization for a drug for human use must have a QPPV. When a company submits an application for permission to bring a medicinal product onto the market, the company submits a description of its system for monitoring the safety of the product in actual use and proof that the services of a QPPV are in place.

Paediatric-use marketing authorisations (PUMA) are granted by the European Medicines Agency (EMA) for medical products that are intended exclusively for paediatric use, that is, for use in patients younger than 18 years. Like ordinary EMA marketing authorisations, a PUMA approval is valid in all countries of the European Economic Area. The PUMA process was established to make it more profitable for pharmaceutical companies to market drugs for children. For this purpose, new data used for PUMA approved drugs are protected for 10 years, and the applications are partially exempt from fees.

Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).

Obiltoxaximab, sold under the brand name Anthim among others, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores.

<span class="mw-page-title-main">Hexavalent vaccine</span> Single vaccine protecting against six individual diseases

A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, Jordan, and New Zealand.

The Spanish Agency of Medicines and Medical Devices is a regulatory and autonomous agency of the Government of Spain that acts as the highest sanitary authority in the country in terms of medical safety on medicines, health products, cosmetics and personal care products.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein.

Teclistamab, sold under the brand name Tecvayli, is a human bispecific monoclonal antibody used for the treatment of relapsed and refractory multiple myeloma. It is a bispecific antibody that targets the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA), which is expressed on the surface of malignant multiple myeloma B-lineage cells.

Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of chronic hypoparathyroidism. It is a transiently pegylated parathyroid hormone.

References

  1. 1 2 "Relocation to Amsterdam". European Medicines Agency. 17 September 2018. Retrieved 16 January 2021.
  2. ↑ "European Medicines Agency (EMA) | European Union". europa.eu. 26 February 2020.
  3. ↑ "Funding | European Medicines Agency (EMA)" (PDF). European Medicines Agency. 8 January 2024.
  4. 1 2 Set up by EC Regulation No. 2309/93 as the European Agency for the Evaluation of Medicinal Products, and renamed by EC Regulation No. 726/2004 to the European Medicines Agency, it had the acronym EMEA until December 2009. The European Medicines Agency does not call itself EMA either – it has no official acronym but may reconsider if EMA becomes commonly accepted (see communication on new visual identity Archived 1 June 2010 at the Wayback Machine and logo Archived 25 December 2009 at the Wayback Machine ).
  5. 1 2 "EMEA becomes EMA". PMLive. 14 December 2009. Archived from the original on 22 November 2022. Retrieved 6 October 2017.
  6. 1 2 Hrabovszki, Georgina (11 March 2019). "EMA now operating from Amsterdam". European Medicines Agency. Retrieved 12 March 2019.
  7. 1 2 "United Kingdom's withdrawal from the European Union ('Brexit')". European Medicines Agency. 17 September 2018. Retrieved 16 September 2019.
  8. ↑ M. Jacobs, David (2015). "European Medicines Agency (EMA)". Encyclopedia of Pharmaceutical Science and Technology (4 ed.). pp. 1449–1460. doi:10.1081/E-EPT4-120050267. ISBN   9781351124874.
  9. ↑ "Who we are". Coalition for Epidemic Preparedness Innovations . Archived from the original on 19 October 2022. Retrieved 16 September 2023.
  10. ↑ "Benefactors of Health Level Seven". Health Level Seven International . Archived from the original on 1 June 2023. Retrieved 17 September 2023.
  11. ↑ "Members & Observers". International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use . Archived from the original on 24 April 2022. Retrieved 17 September 2023.
  12. ↑ "Members & Observers". International Pharmaceutical Regulators Programme. Archived from the original on 24 April 2022. Retrieved 17 September 2023.
  13. ↑ "Cancer Immunotherapy Partnerships and Collaborations". Society for Immunotherapy of Cancer . Archived from the original on 27 March 2023. Retrieved 17 September 2023.
  14. ↑ "Partnerships". Vaccine Confidence Project . Archived from the original on 28 April 2022. Retrieved 17 September 2023.
  15. ↑ "Committee for Medicinal Products Human Use (CHMP)". European Medicines Agency (EMA). 17 September 2018. Retrieved 26 July 2020.
  16. ↑ "Questions and answers on the paediatric use marketing authorisation (PUMA)" (PDF). European Medicines Agency (EMA). 13 September 2011. Archived from the original (PDF) on 15 April 2016.
  17. ↑ "The evaluation of medicines, step-by-step". European Medicines Agency (EMA). 25 November 2023.
  18. ↑ "Complaint filed to the European Medicines Agency over maladministration related to safety of the HPV vaccines". Cochrane Nordic. 2017. Archived from the original on 31 August 2017. Retrieved 16 January 2021.
  19. ↑ Louise Brinth: Responsum to Assessment Report on HPV-vaccines released by EMA November 26th 2015., online (PDF; 1,3 MB) Archived 7 July 2016 at the Wayback Machine
  20. ↑ "Committee for Medicinal Products Veterinary Use (CVMP)". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 27 May 2021. Retrieved 26 July 2020.
  21. ↑ "Orphan designation: Overview". European Medicines Agency. 17 September 2018. Retrieved 26 December 2022.
  22. ↑ "Herbal medicinal products". European Medicines Agency (EMA). 17 September 2018. Retrieved 26 December 2022.
  23. ↑ "Paediatric Regulation". European Medicines Agency (EMA). 17 September 2018. Retrieved 26 December 2022.
  24. ↑ European Medicines Agency (3 December 2019). "Committee for Advanced Therapies (CAT)". European Medicines Agency. Retrieved 3 December 2019.
  25. ↑ European Medicines Agency (3 December 2019). "Pharmacovigilance Risk Assessment Committee (PRAC)". European Medicines Agency. Retrieved 3 December 2019.
  26. ↑ "Marketing authorisation". European Medicines Agency. 17 September 2018. Retrieved 23 March 2021.
  27. ↑ "Annex 5: Countries and Organizations that Contributed to the Elaboration of the GVAP" (PDF). World Health Organization . Decade of Vaccines Collaboration. Archived (PDF) from the original on 17 September 2023. Retrieved 17 September 2023.
  28. ↑ "Offers to host the European Medicines Agency (EMA)". European Council. Retrieved 14 September 2017.
  29. ↑ "Finland is an excellent place for European Medicines Agency". Ministry of Social Affairs and Health. 12 April 2017. Retrieved 18 April 2017.
  30. ↑ Wintour, Patrick (15 February 2017). "Countries line up to host European Medicines Agency after it leaves UK". The Guardian. Retrieved 1 April 2017.
  31. ↑ "Homepage – The Dutch Bid for EMA". The Dutch Bid for EMA. Archived from the original on 14 July 2017. Retrieved 13 July 2017.
  32. ↑ Wintour, Patrick (15 February 2017). "Countries line up to host European Medicines Agency after it leaves UK". The Guardian . Retrieved 8 May 2017.
  33. ↑ Morgan, Sam (23 March 2017). "Romania looks to poach EU medicines agency from UK". Euractiv. Retrieved 8 May 2017.
  34. ↑ "A Brexit pill for Romania". Global Counsel UK. 13 April 2017. Retrieved 8 May 2017.
  35. ↑ Julia Bradshaw (8 December 2016). "Sweden launches campaign to host EU drugs agency instead of UK after Brexit" . The Telegraph. Archived from the original on 12 January 2022. Retrieved 1 April 2017.
  36. ↑ Zapcic, Andreja (29 March 2017). "Kujundžić: Hrvatska je spremna preuzeti Europsku agenciju za lijekove" [Kujundžić: Croatia Is Ready to Take Over the European Medicines Agency] (in Croatian). T-portal. Retrieved 1 April 2017.
  37. ↑ "Strasbourg could trade Parliament seat for medicines agency". Reuters. 10 May 2017. Retrieved 26 December 2022– via Euractiv.
  38. ↑ Underwood, George (27 September 2017). "EMA staff favour move to Amsterdam". Pharma Times. Retrieved 19 October 2017.
  39. 1 2 Vesper, Inga (12 October 2017). "European drug regulation at risk of stalling as agency prepares to leave London". Nature News . Retrieved 13 October 2017.
  40. ↑ Bocci, Michele (20 November 2017). "Ema, Milano passa al secondo turno di votazioni con Amsterdam e Copenhagen" [Ema, Milan passes second in terms of votes with Amsterdam and Copenhangen]. la Repubblica (in Italian). Archived from the original on 9 November 2020. Retrieved 20 October 2017.
  41. ↑ "Coronavirus disease (COVID-19)". European Medicines Agency. 29 January 2020. Archived from the original on 22 September 2021. Retrieved 16 September 2023.
  42. ↑ "ACTIV". National Institutes of Health (NIH). Archived from the original on 11 January 2022. Retrieved 16 September 2023.
  43. ↑ Stubbs, Jack (9 December 2020). "Hackers steal Pfizer/BioNTech COVID-19 vaccine data in Europe, companies say". Reuters . Archived from the original on 16 September 2023. Retrieved 16 September 2023.
  44. ↑ "Cyberattack on EMA – update 5". European Medicines Agency. 15 January 2021. Archived from the original on 16 September 2023. Retrieved 16 September 2023.
  45. ↑ "Statement on EMA Cyberattack". Pfizer . 9 December 2020. Archived from the original on 16 September 2023. Retrieved 16 September 2023.
  46. ↑ Tinari, Serena (10 March 2021). "The EMA covid-19 data leak, and what it tells us about mRNA instability". BMJ. 372: n627. doi: 10.1136/bmj.n627 . ISSN   1756-1833. PMID   33692030.
  47. ↑ Abbasi, Jennifer (13 April 2021). "Data Leak Exposes Early COVID-19 Vaccine Manufacturing Hiccups". JAMA . 325 (14): 1385. doi: 10.1001/jama.2021.5002 . ISSN   0098-7484. PMID   33847730.
  48. ↑ Lovett, Samuel (11 March 2021). "European regulator raised concern over quality of early Pfizer vaccine batches, leaked emails show". The Independent . Archived from the original on 16 September 2023. Retrieved 16 September 2023.
  49. ↑ Committee for Medicinal Products for Human Use (CHMP) (19 February 2021). "European public assessment report (EPAR) – Comirnaty, INN-COVID-19 mRNA Vaccine (nucleoside-modified)" (PDF). European Medicines Agency. Archived (PDF) from the original on 12 September 2023. Retrieved 16 September 2023.
  50. ↑ Kansteiner, Fraser (15 March 2021). "Pfizer's COVID-19 vaccine faced EMA manufacturing concerns ahead of emergency nod: report". Fierce Pharma. Archived from the original on 10 July 2023. Retrieved 16 September 2023.
  51. ↑ Gu, A; Patel, D; Nayak, R (2016). "Chapter 10: Drug shortages". In Fulda, TR; Lyles, A; Wertheimer (eds.). Pharmaceutical Public Policy. CRC Press. pp. 151–160. ISBN   9781498748513.
  52. ↑ Boslaugh, SE (2015). "European Medicines Agency". The SAGE Encyclopedia of Pharmacology and Society. SAGE Publications. ISBN   9781506346182.
  53. ↑ Sherwood, Ted (16 April 2008). "Generic Drugs: Overview of ANDA Review Process" (PDF). Food and Drug Administration. Archived from the original (PDF) on 19 January 2017. Retrieved 30 January 2010.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.